CureVac
CVAC

$3.72

2.2%

Market Cap: 834M

About: CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,100

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 10 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

4% more call options, than puts

Call options by funds: $1M | Put options by funds: $968K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

2.19% less ownership

Funds ownership: 9.84% [Q4 2023] → 7.65% (-2.19%) [Q1 2024]

2% less funds holding

Funds holding: 89 [Q4 2023] → 87 (-2) [Q1 2024]

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

42% less capital invested

Capital invested by funds: $92.7M [Q4 2023] → $53.8M (-$39M) [Q1 2024]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

8%

upside

Avg. target

$11

196%

upside

High target

$18

384%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

JMP Securities Roy Buchanan	384%upside $18	Market Outperform Reiterated	3 Jul 2024
Leerink Partners Mani Foroohar	8%upside $4	Market Perform Downgraded	25 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about CVAC published over the past 30 days

Zacks Investment Research

CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?

CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on N.

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts

CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce.

CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

The deal represents a vote of confidence in the future of the mRNA-based vaccine market.

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK

CureVac (NASDAQ: CVAC ) stock is on the rise Wednesday after the company announced a restructured licensing agreement with GSK (NYSE: GSK ). This new agreement has GSK taking over the development and manufacturing of certain vaccines made by CureVac.

CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vaccines.

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (LSE/NYSE: GSK) and CureVac N.V. (Nasdaq:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA technology to develop novel treatment approaches Company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two new Phase 1 studies by the end of 2026 Cash runway extended into 2028 through combination of new licensing agreement with GSK, reduced operating expenses and enhanced financial discipline TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK has bought from CureVac 5CV.DE, CVAC.O the full rights to develop and manufacture vaccine candidates for influenza and COVID-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.

GSK buys full rights to make COVID, influenza vaccines from CureVac

See News Rankings